AMRA Medical Advises MRI-Based Muscle Assessment Technology Approved for Clinical Use in US and Canada

AMRA Medical, a ground-breaking digital health company and global leader in body composition analysis offering medical device and medical research services, announced today that AMRA has received 510(k) clearance from the FDA and MDEL (Medical Device Establishment Licence) licensing.

AMRA Medical is now permitted to distribute AMRA® BCP Scan (Body Composition Profile) in the US and Canada. The BCP Scan uses muscle and fat biomarkers from magnetic resonance imaging (MRI) scans to provide objective and actionable data to clinicians.

The AMRA® BCP Scan is offered as a medical device service to promote health and wellness. The technology utilizes AMRA’s rapid neck-to-knee MRI protocol, to produce an easy-to-understand and actionable patient-specific report. The report contains patient-specific body composition measurements, such as muscle, fat, and liver fat volumes, with a comparison to normative values based on AMRA’s reference database. The report goes further to compare the patient with others of the same sex and body habitus, making the results even more personalized. The body composition measurements derived from the MR images provide information that may promote healthy lifestyle choices. For instance, if the BCP Scan detects a high level of visceral fat—which is associated with a higher risk of type 2 diabetes and heart disease—a physician evaluating the results may decide to encourage a lifestyle change of his or her patient that has been shown to reduce visceral fat.

Eric Converse, CEO at AMRA, commented: “We are thrilled to expand this technology to the US and Canada. The AMRA® BCP Scan brings health assessment into a new era. Rather than relying on BMI or waist circumference, we have precise fat and muscle measurements so a physician can really see what is going on inside the body.” Converse continued: “Our protocol only adds minutes to an already prescribed MRI, and because we deliver the results through a simple report, clinicians and patients can easily understand the information and potentially use that information to make healthy lifestyle choices.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”